東陽光(600673.SH)擬20.57億元受讓廣東東陽光藥業2型糖尿病治療藥物境內權益
格隆匯11月13日丨東陽光(600673.SH)公佈,為豐富產品種類,提升其市場競爭力,儘早推動該等糖尿病治療領域藥品的轉讓及商業化進程,公司控股子公司宜昌東陽光長江藥業股份有限公司擬以人民幣20.57億元受讓廣東東陽光藥業有限公司研發的焦穀氨酸榮格列淨、利拉魯肽兩項藥品在中國境內的全部權益、利益及依法享有的全部權利和應依法承擔的全部義務。
焦穀氨酸榮格列淨、利拉魯肽為2型糖尿病治療藥物,其中焦穀氨酸榮格列淨為國家1類創新藥,作用機制為鈉-葡萄糖協同轉運蛋白-2(SGLT-2)抑制劑,正在準備工作即將開展III期臨牀試驗;利拉魯肽為生物製劑,作用機制為胰高血糖素樣肽-1(GLP-1)受體激動劑,正在準備工作即將同步開展I期及III期臨牀試驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.